EssilorLuxottica has announced the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand.
RetinAI specialises in artificial intelligence (AI) and data management in eyecare.
EssilorLuxottica said the move reinforces the Group’s med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights that empower healthcare professionals and enhance patient care, the company said.
RetinAI develops advanced tools to collect, process, and grade large-scale retinal images and biomarker datasets.
In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey.
The RetinAI Discovery platform has United States Food and Drug Administration approval and is CE-marked. It applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases.
RetinAI also partners with pharmaceutical companies and research organisations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.
“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey,” said Francesco Milleri, Chairman and CEO at EssilorLuxottica.
“RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation, and surgical excellence. Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring.
“We are ushering in a new era of healthcare, and it will be transformative for patients everywhere,”, Mr Milleri said.
Dr Carlos Ciller, Chairman and CEO of RetinAI/Ikerian AG said joining EssilorLuxottica “marks a defining moment in our journey”.
“From the start, we’ve believed in the power of data and AI to transform patient care. With EssilorLuxottica’s global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact. Together, we’ll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients,” Dr Ciller said.
